At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...
LogicBio is a Cambridge, MA-based genome editin...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the deve...
Citius Pharmaceuticals is a specialty pharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.